Preclinical Evaluation of no-Carrier-Added [131I]Meta-Iodobenzyl Guanidine, for the Treatment of Tumours Transfected with the Noradrenaline Transporter Gene

Title: Preclinical Evaluation of no-Carrier-Added [131I]Meta-Iodobenzyl Guanidine, for the Treatment of Tumours Transfected with the Noradrenaline Transporter Gene

VOLUME: 1 ISSUE: 1

Author(s):M. Boyd, S. Ross, J. Owens, D. Hunter, J. Babich, M. R. Zalutsky, T. G. Hamilton, S. Bell and R. J. Mairs

Affiliation:Department of Radiation Oncology, Cancer Research UK Beatson Laboratories, Garscube Estate, Glasgow G61 1BD, Scotland, UK.

Keywords:noradrenaline transporter, mibg, gene therapy, targeted radiotherapy, xenograft

Abstract: Meta-[131I]iodobenzylguanidine ([131I]MIBG), used for neuroblastoma treatment, binds to the noradrenaline transporter (NAT). After NAT gene transfection, other tumour types might be treatable with [131I]MIBG. At 14 MBq, carrier-added [131I]MIBG (1110 MBq / mg) delayed tumour regrowth in NAT gene-transfected xenografts by 39-days, while no-carrier-added [131I]MIBG ( > 104 GBq / mg) cured 100% of tumours.

Cite this article as:

M. Boyd, S. Ross, J. Owens, D. Hunter, J. Babich, M. R. Zalutsky, T. G. Hamilton, S. Bell and R. J. Mairs, “ Preclinical Evaluation of no-Carrier-Added [131I]Meta-Iodobenzyl Guanidine, for the Treatment of Tumours Transfected with the Noradrenaline Transporter Gene”, Letters in Drug Design & Discovery (2004) 1: 50. https://doi.org/10.2174/1570180043485743

About this journal